Despite the soluble domain of the wild type, TRAIL showed low antitumor efficiency in the first set of clinical trials [2]; its outstanding tumor specificity and safety encouraged the development of numerous strategies exploiting the TRAIL signaling pathway in tumor treatment. Here, TNFSF10 is linked to neoplasm.